Diabetes and beyond: Novo Nordisk plots its future
This article was originally published in Scrip
Executive Summary
A 'super-specialism' in diabetes is clearly working well for Novo Nordisk at present, as the world's largest insulin producer reports total sales growth of 18% in 2012 to DKK78 billion ($14 billion), on strong sales of its diabetes portfolio, in particular Victoza (liraglutide). However, it does not consider this a sustainable long-term plan, if its stated strategic aims are any indication.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.